HH&L Acquisition in an 8-K said it deployed another one-month extension, good until April 9, with the deposit into trust of $380,000 by March 16.
The SPAC has a $460 million deal pending with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectious disease tests. Announced in October, terms call for DiaCarta to receive the approximately $414 million in HH&L’s trust, assuming no redemptions, as well as potential additional financing via PIPE.
HH&L Investment, the SPAC’s sponsor, has agreed to contribute or forfeit certain Class B shares to facilitate financing if the total cash available at closing is less than $40 million.
After April 9, the SPAC has one more monthly extension it can use to get the deal across the finish line. Read more.
